Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2021-04-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
独立董事关于聘请公司2021年度审计机构的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from independent directors regarding the prior approval of the appointment of the company's 2021 annual audit firm. It references regulatory rules and governance standards related to audit appointments. The content is focused on the approval and endorsement of the audit firm rather than the audit report itself. The document length is short (525 characters), and it does not contain any financial statements or audit results. Therefore, it is not an Audit Report (AR) but rather a regulatory or governance-related filing. Given the nature of the document as an official opinion on audit firm appointment, it fits best under Regulatory Filings (RNS) as it does not meet criteria for other more specific categories.
2021-04-28 Chinese
独立董事关于公司控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's controlling shareholders and related parties occupying company funds and the company's external guarantees. It references regulatory notices from the China Securities Regulatory Commission and Shenzhen Stock Exchange listing rules. The content focuses on compliance and assurance about related party transactions and guarantees during the reporting period. The document length is short (724 characters), and it does not contain detailed financial statements or comprehensive financial data. It is a regulatory compliance statement related to governance and financial assurance but not a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR), as it is a standalone audit-related statement about specific financial and compliance matters, not a full annual report or other category. FY 2023
2021-04-28 Chinese
2020年度总经理工作报告
Annual Report Classification · 95% confidence The document is titled as the "2020年度总经理工作报告" (2020 Annual General Manager Work Report) of Chengdu Berry Genomics Co., Ltd. It contains detailed financial data for the year 2020, including revenue, profit, assets, liabilities, and R&D investment. It also discusses the company's business operations, development, and future plans. The document includes comprehensive financial figures and management commentary on the company's performance over the full fiscal year 2020. This matches the characteristics of an Annual Report (10-K), which covers company activity and full financial performance for the year. The document length (5684 characters) is sufficient to contain substantive financial data and analysis, not just an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2020
2021-04-28 Chinese
关于聘请2021年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the appointment of the 2021 financial and internal control audit firm for the company. It details the selection process, qualifications of the audit firm, and approvals by the board and independent directors. The document does not contain any financial statements or audit results itself, but rather is a notice about the engagement of the audit firm for the upcoming audit period. The document length is short (1649 characters) and it is clearly an announcement, not the audit report or annual report itself. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report document. Confidence is high due to clear content and context. FY 2021
2021-04-28 Chinese
2020年度独立董事述职报告（梁子才）
Board/Management Information Classification · 95% confidence The document is titled as an independent director's annual performance report for the year 2020. It details the director's attendance at board and shareholder meetings, opinions expressed on various company matters, supervision activities, and training undertaken during the year. The content focuses on governance, oversight, and the director's duties rather than financial results or audit findings. The document length is relatively short (2284 characters) and it is a narrative report on the director's work rather than a formal financial or audit report. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports.
2021-04-28 Chinese
2020年度独立董事述职报告（李广超）
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report of an independent director (李广超) of the company 成都市贝瑞和康基因技术股份有限公司 for the year 2020. It includes attendance records at board and shareholder meetings, independent opinions on various board matters, supervision activities, and other governance-related duties. The content focuses on the director's duties and governance oversight rather than financial results or audit opinions. The document length is 3185 characters, which is relatively short but contains substantive content about the director's role and activities over the year. This matches the category of Board/Management Information (MANG), which covers announcements or reports about changes or activities of the board or senior management. It is not an Annual Report (10-K), Audit Report (AR), or Management Discussion & Analysis (MDA) because it does not contain financial statements or detailed financial analysis. It is not a Regulatory Filing (RNS) because it is a formal report of the independent director's annual work. Therefore, the best classification is MANG with high confidence.
2021-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.